Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
NCT07089121
This study is recruiting at 3 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
Safety, tolerability and efficacy of Descarte-08 in children, adolescents and young adults with childhood-onset systemic lupus erythematosus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Childhood-onset Systemic Lupus Erythematous
- ANCA-Associated Vasculitis (AAV)
- Juvenile Myasthenia Gravis
- Juvenile Dermatomyositis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 12 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Cartesian Therapeutics
- Last updated on ClinicalTrials.gov
- July 27, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
District of Columbia · 1
- H01- Children's National Hospital · Washington D.C., DC
Missouri · 1
- H03- Washington University School of Medicine · St Louis, MO
Ohio · 1
- Cincinnati Children's Hospital Medical Center · Cincinnati, OH
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.